Success Stories: Rapid EB-1A Approval in 5 Days for Research Specialist in the Field of Cancer Biology with Premium Processing
Client’s Testimonial:
“Thank you very much for this great news! It is much faster than I expected.”
On April 2nd, 2025, we received another EB-1A (Alien of Extraordinary Ability) approval for a Research Specialist in the Field of Cancer Biology (Approval Notice).
General Field: Cancer Biology
Position at the Time of Case Filing: Research Specialist
Country of Origin: Turkey
State of Residence at the Time of Filing: Utah
Approval Notice Date: April 2nd, 2025
Processing Time: 5 days (Premium Processing Requested)
Case Summary:
A dedicated research specialist in cancer biology recently earned EB-1A approval with the assistance of the North America Immigration Law Group (NAILG). His work focuses on advancing immuno-oncology, integrating artificial intelligence into pathology, improving cancer treatment approaches, and contributing to biotechnology innovation. Throughout his career, he has remained committed to developing methods that improve both scientific understanding and patient care.
To continue his research in the United States, he partnered with NAILG to file an EB-1A (Alien of Extraordinary Ability) petition. After carefully reviewing his credentials, including his research achievements and professional recognition, our legal team prepared a detailed petition highlighting his sustained contributions to the field and the national relevance of his work.
He has authored 13 peer-reviewed journal articles, which have been cited 330 times by researchers worldwide. His expertise has also been recognized through his service as a peer reviewer for at least 18 scholarly articles. His research has benefited from funding by respected organizations such as the National Institutes of Health (NIH), the U.S. Department of Defense (DOD), the Qatar National Research Fund, and the Natural Science Foundation of Shanghai.
As one expert recommender noted:
"Without a doubt, [client] has enhanced cancer immunotherapy through his work on CAR T cell reprogramming in solid tumors. His robust skill set in cancer biology is further demonstrated by his numerous publications in esteemed venues. Overall, [client] 's findings on non-genetic reprogramming pathways and their impact on the tumor microenvironment position him as a leading figure in the field of cancer biology in the United States."
His research addresses some of the most pressing challenges in medicine today, including the limitations of current cancer therapies and the integration of AI into healthcare. His findings offer meaningful contributions to improving treatment outcomes and advancing the field of precision medicine.The approval of his EB-1A petition within just five days under Premium Processing reflects both the strength of his professional record and the importance of his ongoing work. At NAILG, we are pleased to have played a role in helping him reach this important milestone and look forward to the continued positive impact of his research.